Clinical Trial: NCT04002401
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Kite, A Gilead Company |
| Information Provided By: | Gilead Sciences |
| Last Update Posted: | 2024-02-20 |
Study Overview
Brief Summary
The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in combination with rituximab, as measured by assessment of response rates in adult participants with relapsed/refractory large B-cell lymphoma.
Official Title
A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)
Conditions
Refractory Large B-cell Lymphoma
Intervention / Treatment
- Biological: Axicabtagene Ciloleucel
- Drug: Rituximab
- Drug: Fludarabine
- Drug: Cyclophosphamide
Other Study ID Numbers
- KT-US-471-0114
- 2019-004803-11
- 2019
Start Date (Actual)
2019-11-05
Primary Completion Date (Actual)
2023-01-30
Study Completion Date (Actual)
2023-01-30
Enrollment (Actual)
27
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Kite, A Gilead Company |
| Information Provided By: | Gilead Sciences |
| Last Update Posted: | 2024-02-20 |
Study Overview
Brief Summary
The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in combination with rituximab, as measured by assessment of response rates in adult participants with relapsed/refractory large B-cell lymphoma.
Official Title
A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)
Conditions
Refractory Large B-cell Lymphoma
Intervention / Treatment
- Biological: Axicabtagene Ciloleucel
- Drug: Rituximab
- Drug: Fludarabine
- Drug: Cyclophosphamide
Other Study ID Numbers
- KT-US-471-0114
- 2019-004803-11
- 2019
Start Date (Actual)
2019-11-05
Primary Completion Date (Actual)
2023-01-30
Study Completion Date (Actual)
2023-01-30
Enrollment (Actual)
27
Study Type
Interventional
Phase
Phase 2